Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RC48”

76 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 76 results

Testing effectiveness (Phase 2)UnknownNCT06000033
What this trial is testing

Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Qilu Hospital of Shandong University 35
Large-scale testing (Phase 3)UnknownNCT04714190
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 351
Testing effectiveness (Phase 2)UnknownNCT05745740
What this trial is testing

RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation

Who this might be right for
Non-small Cell Lung Cancer
RemeGen Co., Ltd. 26
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Large-scale testing (Phase 3)Not Yet RecruitingNCT06944496
What this trial is testing

Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Who this might be right for
Gastric Carcinoma
RemeGen Co., Ltd. 616
Testing effectiveness (Phase 2)Study completedNCT04073602
What this trial is testing

RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer

Who this might be right for
Urothelial Carcinoma
RemeGen Co., Ltd. 19
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06185400
What this trial is testing

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Who this might be right for
Non Small Cell Lung CancerERBB2 Mutation-Related TumorsERBB2 Gene Duplication+1 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 108
Testing effectiveness (Phase 2)Looking for participantsNCT04879329
What this trial is testing

Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 372
Testing effectiveness (Phase 2)Study completedNCT03556345
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 127
Testing effectiveness (Phase 2)Looking for participantsNCT05403242
What this trial is testing

RC48-ADC Combined With S-1 for First-line Treatment of Advanced Gastroesophageal Adenocarcinoma With Moderate Expression of HER2

Who this might be right for
Advanced Gastroesophageal Adenocarcinoma
Chinese PLA General Hospital 42
Testing effectiveness (Phase 2)Looking for participantsNCT06791070
What this trial is testing

RC48-ADC Combined With JS001 for Advanced Extramammary Paget Disease of the Scrotum

Who this might be right for
Paget Disease, ExtramammaryScrotum Disease
Fujian Medical University Union Hospital 20
Testing effectiveness (Phase 2)Looking for participantsNCT06063018
What this trial is testing

RC48 Combined With Tislelizumab for Second-line Treatment of HER2 Expression in Recurrent Cervical Cancer

Who this might be right for
Cervical Cancer Recurrent
Peking Union Medical College Hospital 30
Testing effectiveness (Phase 2)UnknownNCT05113459
What this trial is testing

Disitamab Vedotin Combined With PD-1 and Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer（RC48-C018）

Who this might be right for
Gastric Cancer
Guoxin Li 40
Testing effectiveness (Phase 2)Looking for participantsNCT07194005
What this trial is testing

Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer

Who this might be right for
Gastric Cancer
Fudan University 30
Testing effectiveness (Phase 2)Looking for participantsNCT05957757
What this trial is testing

RC48 Combined With Tislelizumab for Bladder Sparing Treatment in NMIBC With BCG Treatment Failure and HER2 Expression

Who this might be right for
Non-Muscle Invasive Bladder CancerHER2
RenJi Hospital 20
Testing effectiveness (Phase 2)UnknownNCT05601401
What this trial is testing

Phase II Study of RC48-ADC in Treating Patients With Salivary Gland Tumors Expressing HER2

Who this might be right for
Salivary Gland Tumors
Peking Union Medical College Hospital 10
Testing effectiveness (Phase 2)Looking for participantsNCT06730373
What this trial is testing

First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)

Who this might be right for
HER2-positive Gastric CancerMetastatic Gastric CancerUnresectable Gastric Carcinoma
Qilu Hospital of Shandong University 110
Testing effectiveness (Phase 2)Looking for participantsNCT06001086
What this trial is testing

A Phase II Clinical Study of Treatment With Disitamb Vedotin Plus Pyrotinib in HER2-positive Early Breast Cancer

Who this might be right for
Breast Cancer
The First Affiliated Hospital with Nanjing Medical University 70
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07279597
What this trial is testing

A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer

Who this might be right for
Muscle-invasive Bladder Urothelial Carcinoma
Tongji Hospital 45
Large-scale testing (Phase 3)UnknownNCT03500380
What this trial is testing

RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases

Who this might be right for
Breast NeoplasmsBreast DiseasesCapecitabine+3 more
RemeGen Co., Ltd. 301
Load More Results